High Risk Resected Melanoma clinical trials

Explore recruiting high risk resected melanoma clinical trials.

Also recruiting in Europe

High Risk Resected Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)

Poland, Italy, Germany, Sweden, Austria, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

High Risk Resected Melanoma trials by city

High Risk Resected Melanoma in Toronto High Risk Resected Melanoma in Vancouver High Risk Resected Melanoma in Montreal High Risk Resected Melanoma in Calgary High Risk Resected Melanoma in Edmonton High Risk Resected Melanoma in Ottawa High Risk Resected Melanoma in Winnipeg High Risk Resected Melanoma in Quebec City High Risk Resected Melanoma in Hamilton High Risk Resected Melanoma in Kitchener High Risk Resected Melanoma in London High Risk Resected Melanoma in Halifax High Risk Resected Melanoma in New York High Risk Resected Melanoma in Los Angeles High Risk Resected Melanoma in Chicago High Risk Resected Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease